NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

GT Biopharma, Inc. (GTBP) Stock Analysis

GT Biopharma, Inc. (GTBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GTBP

$0.24

−$0.01 (−4.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GTBP with… →

GTBP Key Statistics

As of Sep 4, 2026
Trading
Open
$0.26
Previous Close
$0.25
Day's Range
0.22–0.26
52-Week Range
0.22–1.37
Volume
1.16M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.91
Valuation
Market Cap
$10.87M
P/E Ratio
0.05
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.05
EPS (ttm)Profit attributable to each share over the last twelve months.
5.21
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$28.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.11M
1-Year Return
−74.06%
Dividend and dates
Avg Volume
813.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GTBP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.30%
2025−74.26%
2024−60.13%
2023−71.22%
2022−70.95%
2021−57.69%
2020+423.46%
2019−87.54%
2018 (partial year)−60.84%

As of September 4, 2026.

GTBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$28.35M—
2024$0.00−$13.16M—
2023$0.00−$7.60M—
2022$0.00−$20.88M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.42M−$28.35M—
2024$0.00—−$14.36M−$13.16M—
2023$0.00—−$13.58M−$7.60M—
2022$0.00—−$21.26M−$20.88M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GTBP Valuation vs Biotechnology Median

Median of 656 stocks
MetricGTBPBiotechnology medianvs median
P/E0.0512.570.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

GT Biopharma, Inc. (GTBP) is capitalised at $10.87M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 1.

The most recent close on file for GTBP is $0.24, dated September 4, 2026. That is −$0.01 (−4.37%) against the previous close. The 52-week range on file runs from $0.22 to $1.37. The latest close sits 8.51% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $28.35M. Profit margin runs at 0%. Trailing earnings per share are 5.21.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

GTBP trades at a trailing price-to-earnings ratio of 0.05. That is 0 times the Biotechnology median of 12.57. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.05. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −74.06%. Across 5 years the annualized return works out at −75.09%. The reported beta is 0.91. Daily returns over the trailing 8 years annualize to a volatility of 129.04%.

Growth & Income

No dividend is on file for GTBP.

2026 is still running; the price is −69.30% year to date. Across the complete calendar years on file, 2020 returned +423.46% and 2019 returned −87.54%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

GT Biopharma, Inc. (GTBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
GT Biopharma, Inc. GTBP $10.87M 0.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. GT Biopharma, Inc. trades at a P/E of 0.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Visit website →